MapLight
MapLight is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at MapLight.
Frequently Asked Questions
Who founded MapLight?
MapLight was founded by Thomas Layton (Founder).
MapLight is a company.
Key people at MapLight.
MapLight was founded by Thomas Layton (Founder).
Key people at MapLight.
MapLight was founded by Thomas Layton (Founder).
MapLight Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for brain and central nervous system (CNS) disorders, such as schizophrenia, autism spectrum disorder, Alzheimer's disease psychosis, Parkinson's disease, and related conditions.[1][2][3][7] It applies a proprietary discovery platform combining circuit-level neuroscience techniques—like optogenetics, STARmap, and transcriptomics—to identify and modulate malfunctioning neural circuits, addressing limitations of traditional generalized treatments that often have moderate efficacy and significant side effects.[1][3][7] The company serves patients with debilitating brain disorders and their families, solving the lack of precise, circuit-specific pharmacotherapies.[2][4]
MapLight, based in the San Francisco Bay Area (San Francisco and Redwood City), has raised over $600 million in funding, including a $372.5 million oversubscribed Series D in July 2025 co-led by Forbion and Goldman Sachs Alternatives, and a $258.9 million IPO in 2025 offering 14.75 million shares at $17 each.[1][4][6] Its pipeline features multiple drug candidates in clinical and preclinical stages, with two lead compounds in trials showing promise across indications; growth momentum is strong, validated by top-tier investors like Novo Holdings, Arch Venture Partners, 5AM Ventures, and Sanofi.[1][2][3][4][5]
Founded in 2018 by Christopher Kroeger, M.D., M.B.A., a globally recognized leader in psychiatry and neuroscience, MapLight emerged from the need to create circuit-specific treatments for brain disorders where existing options fall short.[1][2][4] Kroeger, now CEO, drew on expertise from academic collaborations in the San Francisco Bay Area biotech hub to build a platform targeting neural circuits causally linked to diseases like schizophrenia and autism.[1][2] Early traction came from proprietary innovations in optogenetics and advanced mapping technologies, leading to a robust pipeline and rapid funding: Series C ($225 million) in late 2024, followed by the massive Series D and IPO in 2025.[1][3][6] Pivotal moments include partnerships with leading research institutes and securing investments from heavyweights like Goldman Sachs and Novo Holdings, fueling clinical advancement.[1][4][5]
MapLight stands out in neuroscience biotech through:
MapLight rides the wave of precision neuroscience and AI-driven drug discovery, capitalizing on advances in brain mapping technologies amid rising demand for targeted CNS therapies—a market strained by high unmet needs in disorders affecting millions, where current treatments fail 30-50% of patients due to side effects and inefficacy.[1][3] Timing is ideal post-2025, with biotech IPO resurgence and investor appetite for multi-asset platforms in a sector projected to grow as aging populations drive Alzheimer's/Parkinson's prevalence.[1][4] Favorable forces include academic-pharma collaborations, AI enhancements in transcriptomics, and regulatory tailwinds for innovative modalities. MapLight influences the ecosystem by pioneering circuit-specific approaches, potentially licensing its platform to others and setting new standards that could reduce development risks and costs industry-wide.[1][2][3]
MapLight is poised for Phase 2/3 trial readouts and potential partnerships or approvals in 2026-2028, leveraging its $600M+ war chest to expand the pipeline and enter commercialization.[1][4] Trends like AI-neuroscience integration and CNS market expansion (e.g., via optogenetics scalability) will propel growth, though execution risks in late-stage trials remain. Its influence could evolve from innovator to category leader, redefining brain disorder care and delivering first-in-class therapies that "map the light" of neural networks—echoing its mission to transform lives where few options exist today.[1][2][7]
